Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs w… Read more
Rapport Therapeutics, Inc. Common Stock (RAPP) - Net Assets
Latest net assets as of September 2025: $511.62 Million USD
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) has net assets worth $511.62 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($535.32 Million) and total liabilities ($23.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $511.62 Million |
| % of Total Assets | 95.57% |
| Annual Growth Rate | 295.34% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Rapport Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rapport Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of Rapport Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $305.43 Million | +1291.49% |
| 2023-12-31 | $-25.63 Million | -231.42% |
| 2022-12-31 | $19.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rapport Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11309300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | 0.01% |
| Other Comprehensive Income | $-522.00K | -0.17% |
| Other Components | $429.66 Million | 140.67% |
| Total Equity | $305.43 Million | 100.00% |
Rapport Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Rapport Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NorthWest Healthcare Properties Real Estate Investment Trust
TO:NWH-UN
|
$849.29 Million |
|
Beijing eGOVA
SHE:300075
|
$849.29 Million |
|
OC Oerlikon Corporation AG
OTCGREY:OERLF
|
$849.73 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
$850.04 Million |
|
Central Securities Corporation
NYSE MKT:CET
|
$848.88 Million |
|
Nongshim
KO:004370
|
$848.40 Million |
|
Strait Innovation Internet Co Ltd
SHE:300300
|
$848.29 Million |
|
Rithm Property Trust Inc.
OTCGREY:RPTCV
|
$848.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rapport Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -25,634,000 to 305,427,000, a change of 331,061,000.
- Net loss of 78,307,000 reduced equity.
- New share issuances of 221,618,000 increased equity.
- Other comprehensive income decreased equity by 526,000.
- Other factors increased equity by 188,276,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-78.31 Million | -25.64% |
| Share Issuances | $221.62 Million | +72.56% |
| Other Comprehensive Income | $-526.00K | -0.17% |
| Other Changes | $188.28 Million | +61.64% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Rapport Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 28.60x to 1.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.97 | $27.73 | x |
| 2023-12-31 | $-1.42 | $27.73 | x |
| 2024-12-31 | $14.73 | $27.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rapport Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-25.64%) is above the historical average (-26.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -54.61% | 0.00% | 0.00x | 1.62x | $-12.60 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.22 Million |
| 2024 | -25.64% | 0.00% | 0.00x | 1.03x | $-108.85 Million |
Industry Comparison
This section compares Rapport Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $511.62 Million | -54.61% | 0.05x | $849.05 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |